NewsHK
In the pre-commercial phase of the biotech cycle, how a company bridges its cash requirements between milestones shapes the balance sheet as much as any pipeline result.
(Nasdaq: HURA), listed on the Nasdaq Capital Market, drew an additional $1,500,000 from its revolving credit facility with Parkview Holdings One LLC on September 2, 2026, disclosing the transaction in a Form 8-K filed with the Securities and Exchange Commission on September 4.
The Loan Agreement with Parkview was first executed on April 21, 2026, with TuHURA disclosing that arrangement to the SEC via an 8-K filed the following day.
The facility carries a maximum availability of $50 million and matures on April 21, 2031.
Keep reading